Fig. (S4) A) Disease Activity Score in 28 joints (DAS28) (median and interquartile ranges) after 22 weeks of IFX treatment for patients with rheumatoid arthritis (RA) with infliximab (Ifx) trough levels (ITL) above and below the week 6 predictive cut-off. B) Patients (%) with EULAR response (good and moderate) at W22, according to the week 6 ITL cut-off.